<DOC>
	<DOCNO>NCT02192619</DOCNO>
	<brief_summary>The registry aim document epidemiologic data , treatment long-term outcome well quality life patient APL . Additionally , biobanking project translational study integrate . Prospective population-based non-interventional non-randomized multicenter registry .</brief_summary>
	<brief_title>National Acute Promyelocytic Leukemia ( APL ) Observational Study NAPOLEON-Registry German AML Intergroup</brief_title>
	<detailed_description>- collection epidemiological data APL : age distribution , prognostic factor , distribution subgroup , incidence - documentation efficacy safety first line salvage therapy APL include - documentation minimal residual disease ( MRD ) - correlation clinical outcome choose therapy - collection evaluation quality life - validation publish prognostic factor / new potential prognostic factor - acquisition bone marrow , peripheral blood buccal swab sample biobanking translational study umbrella specific study-group biobanking concept</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Promyelocytic , Acute</mesh_term>
	<criteria>newlydiagnosed APL ( either de novo therapyrelated ) , within 12 month diagnosis relapse APL , within 12 month diagnosis relapse 1. confirm presence translocation ( 15 ; 17 ) 2. / confirm detection fusion transcript PML/RARa</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>APL</keyword>
	<keyword>acute promyelocytic leukemia</keyword>
	<keyword>AML M3</keyword>
</DOC>